GSK to buy Canadian biopharm firm Bellus Health for $2 billion

Bellus Health's lead new drug candidate is a treatment for chronic cough, a condition that afflicts an estimated 28 million people worldwide.

Previous Denver banker turned nonprofit chief built legacy of finance programs for Colorado kids
Next Cherry Hills mansion sells for $7.3M, tops March sales